AstraZeneca completes acquisition of Neogene Therapeutics
Roland Magnusson/iStock Editorial via Getty Images                 

AstraZeneca (NASDAQ:AZN) said on Monday that it completed the acquisition of Neogene Therapeutics in a deal worth up toÂ $320M.
Neogene, which is developing next-generation T-cell receptor therapies for solid cancers,Â will operate as a unit of AstraZeneca, with operations in Amsterdam, the Netherlands and California.
The deal was announced in November 2022.
The British pharma giant added that it acquired all outstanding equity of Neogene for an initial payment of $200M.
AstraZeneca will also pay up to $120M in additional contingent milestone-based and non-contingent consideration, according to the company.